Pneumococcal Vaccination After Prevnar 13 at Age 84
You should receive PPSV23 (Pneumovax 23) at least 1 year after your Prevnar 13 vaccination. This is the standard recommendation for immunocompetent adults aged ≥65 years who have received PCV13.
Timing and Rationale
According to the most recent 2024 ACIP guidelines, for adults aged ≥65 years who have received PCV13 only, you have several options 1:
- PPSV23: Administer ≥1 year after the PCV13 dose
- PCV20 or PCV21: Administer ≥1 year after the PCV13 dose (newer, broader coverage options)
The ≥1 year interval is critical because:
- It allows optimal immune response development from the conjugate vaccine 2
- Shorter intervals may result in diminished immune responses 3
- Research demonstrates that PCV13 followed by PPSV23 produces superior and more durable antibody responses compared to the reverse sequence 4, 3
Why This Sequence Matters
The order of vaccination is crucial. Studies consistently show that giving PCV13 first (which you've already done) followed by PPSV23 produces:
- Higher opsonophagocytic activity (OPA) titers for most shared serotypes 3
- More durable immune responses lasting at least 1-3 years 4, 5
- Better mucosal-directed immunity 5
In contrast, giving PPSV23 first significantly impairs the response to subsequent PCV13 for all serotypes 3. Since you received PCV13 first, you're on the optimal pathway.
Current Best Options
Option 1: PPSV23 (Traditional Approach)
- Covers 23 serotypes (12 overlap with PCV13, plus 11 additional)
- These additional 11 serotypes account for 32-37% of invasive pneumococcal disease in adults ≥65 years 2
- Well-established safety profile 2
Option 2: PCV20 or PCV21 (Newer Approach)
- PCV20/PCV21 provide broader coverage with additional serotypes not in PCV13
- Can be given as a single dose without need for subsequent PPSV23 1
- Important caveat: PCV21 does NOT contain serotype 4, which may be relevant in certain geographic areas (particularly western US) where serotype 4 causes ≥30% of pneumococcal disease 1
Clinical Decision-Making
For most patients, PPSV23 remains the standard and cost-effective choice after PCV13 2. However, discuss with your provider whether PCV20 or PCV21 might be preferable based on:
- Local pneumococcal serotype epidemiology
- Your specific risk factors
- Vaccine availability
- Cost considerations
Important Considerations
- Do not receive another dose before the 1-year mark from your PCV13 vaccination
- If you have immunocompromising conditions, CSF leak, or cochlear implant, the interval can be shortened to ≥8 weeks, but this doesn't appear to apply to your situation 2
- After receiving PPSV23 at age ≥65 years, no additional pneumococcal vaccines are routinely needed unless you opt for shared clinical decision-making regarding PCV20/PCV21 ≥5 years later 1
Bottom line: Schedule your PPSV23 (or discuss PCV20/PCV21 alternatives) with your provider now if it has been ≥1 year since your Prevnar 13 vaccination.